Michael E. Gallion

Array ( [id] => 18310908 [patent_doc_number] => 20230114808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => THERAPEUTIC RNA FOR PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/310773 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17838063 [patent_doc_number] => 20220275368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => NEW TREATMENTS INVOLVING MIRNA-193A [patent_app_type] => utility [patent_app_number] => 17/630457 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17579212 [patent_doc_number] => 20220136067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => KIT, DEVICE, AND METHOD FOR DETECTING UTERINE LEIOMYOSARCOMA [patent_app_type] => utility [patent_app_number] => 17/435161 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17671064 [patent_doc_number] => 20220184231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => CLOSED-ENDED DNA (CEDNA) AND IMMUNE MODULATING COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/435419 [patent_app_country] => US [patent_app_date] => 2020-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595742 [patent_doc_number] => 20220145316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/433965 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17433965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426947 [patent_doc_number] => 20220054655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => OXR1 GENE THERAPY [patent_app_type] => utility [patent_app_number] => 17/431793 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297829 [patent_doc_number] => 20210393668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => USE OF OLIGONUCLEOTIDES FOR THE TREATMENT OF TUMORS [patent_app_type] => utility [patent_app_number] => 17/425019 [patent_app_country] => US [patent_app_date] => 2020-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370327 [patent_doc_number] => 20220025379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS OF TREATING SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS [patent_app_type] => utility [patent_app_number] => 17/413384 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342121 [patent_doc_number] => 20220008452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NASH, NAFLD, DIABETES, ATHEROSCLEROSIS, AND/OR OBESITY [patent_app_type] => utility [patent_app_number] => 17/311502 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428736 [patent_doc_number] => 20220056444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/298896 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -86 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18180449 [patent_doc_number] => 20230041178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXAPNSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/299275 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -83 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336391 [patent_doc_number] => 20220002722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL [patent_app_type] => utility [patent_app_number] => 17/293303 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343979 [patent_doc_number] => 20220010310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => An lncRNA integrates a DNA-PK-mediated DNA damage response and vascular senescence [patent_app_type] => utility [patent_app_number] => 17/291922 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503415 [patent_doc_number] => 20220096517 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => MicroRNA Compounds and Methods for Modulating MIR-10B Activity [patent_app_type] => utility [patent_app_number] => 17/290298 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355469 [patent_doc_number] => 20220016265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => MESSENGER RNA THERAPY FOR TREATMENT OF OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/292673 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299913 [patent_doc_number] => 20210395752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => VDAC1 SILENCING MOLECULES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/289822 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292582 [patent_doc_number] => 20210388421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => METHOD FOR DETECTION OF SPECIFIC NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/291792 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17789599 [patent_doc_number] => 20220248690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => SEX-LINKED RNAI INSECTICIDE MATERIALS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/288748 [patent_app_country] => US [patent_app_date] => 2019-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533881 [patent_doc_number] => 20220112490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => METHOD FOR SUPPRESSING PROTEIN TRANSLATION REACTION USING STAPLE NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 17/287563 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20535988 [patent_doc_number] => 12553054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Compositions and methods related to nucleic acid anticoagulants [patent_app_type] => utility [patent_app_number] => 17/285371 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 11247 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285371 [rel_patent_id] =>[rel_patent_doc_number] =>)